Cassava Sciences Announces Interim Safety Review Of Simufilam On-Going Phase 3 Trials In Patients With Alzheimer's Disease; DSMB Recommended The Phase 3 Trials Of Simufilam Continue As Planned, Without Modification
Portfolio Pulse from Benzinga Newsdesk
Cassava Sciences, Inc. (NASDAQ:SAVA) announced a positive interim safety review of simufilam in ongoing Phase 3 clinical trials for Alzheimer's disease. The Data and Safety Monitoring Board (DSMB) recommended that both of Cassava Sciences' Phase 3 studies of simufilam continue as planned, without modification. Patient enrollment is expected to be completed for both Phase 3 studies by the end of 2023.
September 18, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cassava Sciences' Phase 3 trials of simufilam for Alzheimer's disease received a positive interim safety review, which could boost investor confidence in the company.
The positive interim safety review indicates that the trials are proceeding as planned without any major safety concerns. This could increase investor confidence in the company and its product, potentially leading to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100